Mefloquine Poisoning now has a Name.

The Quinism Foundation, Incorporated is a Vermont Domestic Non-Profit Corporation exempt from federal income tax under section 501(c)(3) of the Internal Revenue Code
Your donation will support the development of our online presence and our initial outreach efforts.
Donations by check or money order in support of The Quinism Foundation may also be sent to P.O. Box 145, White River Junction, VT 05001 USA

Join our mailing list for regular updates.

Press Releases

The Quinism Foundation Incorporates As a Non-profit Corporation


The Foundation Supports Education and Research on Chronic Quinoline Encephalopathy, a Medical Condition That Can Mimic PTSD

The Quinism Foundation Calls on Public Health England to Update its Malaria Chemoprophylaxis Recommendations


UK Drug Regulators Now Warn that Symptoms of Sleep Disturbance During Use of Mefloquine Require the Drug's Immediate Discontinuation

The Quinism Foundation Supports Australian Veterans' Calls for Chronic Quinoline Encephalopathy to be Recognized as a Compensable Disorder


The Foundation Supports the Quinoline Veterans and Families Association in its Submission Related to Poisoning by Mefloquine, Tafenoquine, and Primaquine

Executive Director

A Message from the Executive Director

Dear Supporter,

The term "quinism" may seem new, but no doubt the symptoms of mefloquine poisoning are all too familiar: Tinnitus. Dizziness. Vertigo. Paresthesias. Visual disturbances. Nightmares. Insomnia. Anxiety. Cognitive dysfunction. Depression. Personality change. Suicidal thoughts.

We know the cause of these symptoms: Poisoning by a drug that is neurotoxic and that injures the brain. Poisoning that causes a disease.

It's time for this disease to be named. The disease is chronic quinoline encephalopathy — also known as neuropsychiatric quinism.

The Quinism Foundation is a new 501(c)(3) nonprofit organization established to support education and research on chronic quinoline encephalopathy and other medical conditions caused by poisoning, or intoxication, by mefloquine and related quinoline drugs, including tafenoquine — a new quinoline drug, even more neurotoxic than mefloquine — now under review by international drug regulators.

Please take a moment to sign up for our mailing list. In the coming weeks, you will begin to receive regular updates from the foundation. You will also learn about how to get involved and support the foundation's activities.

In the meantime, you can learn more by reading this press release announcing the foundation's incorporation, and you can sign up to learn more about our upcoming Annual Meeting, scheduled for Monday, April 30, 2018 through Tuesday, May 1, 2018, in White River Junction, Vermont. Save the dates!

On behalf of The Quinism Foundation, I thank you in advance for your support. I am confident that together, we can make a difference in the fight against quinism. I hope that you will join us.


Remington Nevin, MD, MPH, DrPH
Executive Director, The Quinism Foundation